SCHEMBL25568464

SCHEMBL25568464

C=C1CC2(C1)CC(NC(=O)OC(C)(C)C)C2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.43
GAA P10253 2/20 0.42
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
EPHX2 P34913 1/20 0.41
CTSK P43235 2/20 0.40
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
KMT2A Q03164 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KCNA3 P22001 1/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD11B1 P28845 1/20 0.36
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452519 0.86 GAA (0.47) BTKGAANFKB1NFKB2RELA
SCHEMBL14669045 0.82 BTK (0.49) BTKGAANFKB1NFKB2RELA
SCHEMBL571098 0.80 BTK (0.50) BTKGAANFKB1NFKB2RELA
SCHEMBL21228026 0.79 BTK (0.46) BTKGAANFKB1NFKB2RELA
SCHEMBL19358642 0.79 BTK (0.46) BTKGAANFKB1NFKB2RELA
SCHEMBL18616097 0.79 BTK (0.46) BTKGAANFKB1NFKB2RELA
SCHEMBL19381847 0.79 BTK (0.50) BTKGAANFKB1NFKB2RELA
SCHEMBL24751681 0.78 BTK (0.45) BTKGAANFKB1NFKB2RELA
SCHEMBL8894795 0.78 BTK (0.45) BTKGAANFKB1NFKB2RELA
SCHEMBL15845050 0.78 BTK (0.45) BTKGAANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM BTK 88/4885GAA 1109/4885NFKB1 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.